CAPLIPOINT - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.4
| Stock Code | CAPLIPOINT | Market Cap | 12,990 Cr. | Current Price | 1,709 ₹ | High / Low | 2,397 ₹ |
| Stock P/E | 35.9 | Book Value | 243 ₹ | Dividend Yield | 0.35 % | ROCE | 28.6 % |
| ROE | 22.0 % | Face Value | 2.00 ₹ | DMA 50 | 1,707 ₹ | DMA 200 | 1,843 ₹ |
| Chg in FII Hold | -0.43 % | Chg in DII Hold | 0.09 % | PAT Qtr | 87.3 Cr. | PAT Prev Qtr | 103 Cr. |
| RSI | 51.2 | MACD | 21.8 | Volume | 59,539 | Avg Vol 1Wk | 68,815 |
| Low price | 1,500 ₹ | High price | 2,397 ₹ | PEG Ratio | 1.63 | Debt to equity | 0.00 |
| 52w Index | 23.3 % | Qtr Profit Var | 16.8 % | EPS | 47.7 ₹ | Industry PE | 30.1 |
📊 Financials: CAPLIPOINT shows strong fundamentals with ROE at 22.0% and ROCE at 28.6%, reflecting excellent efficiency. EPS of ₹47.7 supports valuation strength. However, quarterly PAT declined from ₹103 Cr. to ₹87.3 Cr. (down 16.8%), raising short-term concerns. Debt-to-equity is 0.00, highlighting a debt-free balance sheet.
💹 Valuation: The stock trades at a P/E of 35.9, above the industry average of 30.1, indicating premium valuation. P/B ratio is ~7.0, suggesting expensive pricing relative to book value. PEG ratio of 1.63 implies growth is fairly priced. Intrinsic value appears slightly lower than current levels, requiring cautious entry.
🏢 Business Model: CAPLIPOINT operates in the pharmaceutical sector, benefiting from strong demand for specialty formulations. Competitive advantage lies in high efficiency metrics (ROE, ROCE) and debt-free operations. Institutional sentiment is mixed, with FII holdings down (-0.43%) but DII holdings up (+0.09%).
🎯 Entry Zone: Ideal entry between ₹1,690–1,710, near 50 DMA support. Long-term investors may hold for 3–5 years, with exit triggers if ROE falls below 18% or earnings growth slows.
Positive
- Strong ROCE of 28.6% and ROE of 22.0%.
- Debt-free balance sheet ensures financial stability.
- EPS of ₹47.7 supports valuation strength.
- DII holdings increased (+0.09%), showing domestic institutional support.
Limitation
- High P/E of 35.9 compared to industry average of 30.1.
- PEG ratio of 1.63 indicates growth is fairly priced.
- Quarterly PAT declined by 16.8% (₹103 Cr. to ₹87.3 Cr.).
- FII holdings decreased (-0.43%), showing reduced foreign investor confidence.
Company Negative News
- Quarterly profit decline raises concerns on near-term earnings momentum.
Company Positive News
- Strong long-term fundamentals with debt-free status.
- DII holdings increased, reflecting domestic institutional support.
Industry
- Pharmaceutical sector trades at an average P/E of 30.1.
- CAPLIPOINT’s premium valuation reflects strong fundamentals but requires growth consistency.
Conclusion
✅ CAPLIPOINT is a fundamentally strong pharmaceutical stock with excellent ROE, ROCE, and debt-free status. Despite premium valuation and recent profit decline, it remains a solid candidate for long-term investment. Entry near ₹1,690–1,710 offers value, with a 3–5 year horizon recommended. Monitor earnings growth, institutional sentiment, and technical indicators for timely exit signals.